Shanghai, China - Suzhou MicroPort® OrthoRecon Co, Ltd. recently received registration certificates for its independently developed hip implant components of wedge-shape femoral stem (“femoral stem”) and metal femoral head from National Medical Products Administration of China (NMPA).
The Chinese-made wedge-shape femoral stem is made of titanium alloy with a wedge shaped design, which features outstanding proximal femoral initial stability. The double tapered design of the femoral stem can effectively provide rotational stability and conserve bone stock. The titanium ion coated surface of the stem body is designed to offer more excellent bone apposition. The metal femoral head is made of CoCrMo with multiple models for clinical application, which can meet most of the clinical needs of hip arthroplasty.
The approved femoral stem can be used in combination with MicroPort® Orthopedics’ SuperPATH® Supercapsular Percutaneously Assisted Total Hip Arthroplasty (“SuperPATH®”). SuperPATH® is the world’s first minimally invasive hip posterior approach procedure. SuperPATH® features not only small incisions of the sized between 6 and 8 centimeters but also no cutting of muscles and tendons, and removal of capsules. There are less blood loss and pains. A series of post-operative complications, including dislocation, DVT risk and nerve palsy, are also greatly reduced. More patients can get back to their feet on the same day or even a few hours after the procedure, so that the recovery time is significantly cut to save perioperative costs. SuperPATH® has become the most advanced representative within the orthopedic fast recovery landscape.
MicroPort® Orthopedics China President Mr. Robin Weng said, “The acquisition of the approvals for the new Chinese-made femoral stem and metal femoral head has further enriched and improved the Chinese-made joint product lines of MicroPort® Orthopedics and quickened the paces of MicroPort® Orthopedics’ Chinese-made joint business to provide comprehensive product offerings. MicroPort® Orthopedics will keep a continuing commitment to the R&D and promotion of new orthopedic techniques, new rationales and new products to provide patients with high-quality medical solutions that can improve their quality of life.”